This group also suggested the importance of an allogeneic “off-the-shelf” production of LMP/EBNA1-specific T cells in an attempt to increase the frequency and efficacy of these cells to enable their clinical use in the treatment of NPC (10). This evidence concerns the gene PDLIM7 and nasopharyngeal carcinoma.